This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Thomas Baltimore Steps Down As Director Of Integra LifeSciences

PLAINSBORO, N.J., Aug. 27, 2012 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) announced that Thomas J. Baltimore, Jr. has resigned from its Board of Directors to focus on his role as Chief Executive Officer of RLJ Lodging Trust (NYSE:RLJ) and to reduce his outside board commitments. Mr. Baltimore has served as an independent director since 2007 and also as a member of the Compensation Committee.

Stuart Essig, Integra's Chairman, stated, "We would like to thank Tom for his valuable service to the Board. We recognize his insight and the substantial time and effort he has devoted to Integra, and his contributions will be missed. We wish him success in his future endeavors."

The Board appointed Christian S. Schade to serve on the Compensation Committee to fill the vacancy created by Mr. Baltimore. As a result of Mr. Baltimore's resignation, the Board is reducing the size of the board from 10 seats to nine.

About Integra

Integra LifeSciences, a world leader in medical devices, is dedicated to limiting uncertainty for surgeons, so they can concentrate on providing the best patient care. Integra offers innovative solutions in orthopedics, neurosurgery, spine, reconstructive and general surgery. For more information, please visit www.integralife.com

CONTACT: John B. Henneman, III
         Executive Vice President, Chief Financial Officer
         (609) 275-0500
         jack.henneman@integralife.com
         
         Angela Steinway
         Investor Relations
         (609) 936-2268
         angela.steinway@integralife.com

Company Logo

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,080.14 +21.45 0.12%
S&P 500 2,117.69 +4.76 0.23%
NASDAQ 5,092.0850 +36.0220 0.71%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs